2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
2 Nov 2023
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Value of mentorship
Responding to reviewers
How to write a good paper for a top journal
Finding Grants and writing a good grant proposal
Critical appraisal of a published literature
Biostatistics for clinician researchers 1: Correlation and regression analysis
Using social media media effectively for medical research and education
Biostat for Clinician Researchers 1: Correlation and Regression Analysis
Writing a protocol
Welcome from NHRC
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer